Laguna Tech
Private Company
Funding information not available
Overview
Laguna Tech is an early-stage, pre-revenue medical device company targeting a significant unmet need in structural heart disease: the treatment of pure or predominant Aortic Regurgitation (AR) with a transcatheter solution. Its core innovation, the ZETA valve, is a hybrid device combining features of balloon-expandable and self-expanding technologies to securely anchor in non-calcified anatomy, a key challenge in AR. The company has initiated first-in-human (FIH) clinical trials, reporting six successful initial cases, and is positioning itself to capture a share of the multi-billion dollar TAVR market by addressing a patient population with no currently approved transcatheter devices in the US.
Technology Platform
Hybrid transcatheter heart valve platform combining balloon-expandable and self-expanding technologies for secure anchoring in both calcified (stenotic) and non-calcified (regurgitant) aortic valve anatomies.
Opportunities
Risk Factors
Competitive Landscape
Laguna Tech's primary competition is the off-label use of existing TAVR valves from Edwards Lifesciences and Medtronic, which are suboptimal for AR. It also competes with other startups and potentially with next-generation valves from giants designed for expanded indications. Its success hinges on proving superior safety and efficacy for AR compared to these off-label options.